Skip to main content
PolicySpeak
← All legislative files
Regulation (EU) 2022/6412021/0432(COD)COM(2021)998

Derogation from certain obligations concerning investigational medicinal products made available in the United Kingdom with respect to Northern Ireland as well as in Cyprus, Ireland and Malta

Amending Regulation (EU) No 536/2014 as regards a derogation from certain obligations concerning investigational medicinal products made available in the United Kingdom with respect to Northern Ireland as well as in Cyprus, Ireland and Malta

Stage
In force, reached 20 Apr 2022
In force
In force since 31 Jan 2022 · CELEX 32022R0641
Procedure
Ordinary legislative procedure
Rapporteur
Pascal Canfin (Renew)
Lead DG
DG SANTE
Last activity
14 Jun 2022
18 entries · record as of 14 Sept 2026

Where it stands

Latest: Discussions within the Council or its preparatory bodies, 14 Jun 2022.

Show the earlier record: 5 dates, 17 Dec 2021 to 9 Mar 2022
  1. 17 Dec 2021
    • Adoption by Commission
  2. 20 Dec 2021
    • Discussions within the Council or its preparatory bodies
  3. 20 Jan 2022
    • Plenary sitting
    • Referred to committee
  4. 1 Mar 2022
    • Discussions within the Council or its preparatory bodies
  5. 9 Mar 2022
    • Discussions within the Council or its preparatory bodies
  1. 16 Mar 2022
    • Feedback on adopted proposal closed: derogations concerning investigational medicinal products in NI IE CY and MT, 1 responses · Commission
  2. 4 Apr 2022
    • Plenary sitting
  3. 5 Apr 2022
    • Plenary vote
  4. 7 Apr 2022
    • Discussions within the Council or its preparatory bodies
    • EP position at first reading
    • Plenary amended the proposal
    • Plenary vote
  5. 12 Apr 2022
    • Approval of the EP's first reading position by the Council (adoption of the legislative act)
    • Signed
  6. 20 Apr 2022
    • Published in the Official Journal
  7. 2 May 2022
    • Plenary sitting
  8. 14 Jun 2022
    • Discussions within the Council or its preparatory bodies
5 people

Who is on it

The Parliament's rapporteurs, shadow rapporteurs and opinion rapporteurs currently on this file.

RoleNameGroupCountryCommittee
RapporteurPascal CanfinRenewFRENVI
Shadow rapporteurBas EickhoutGreens/EFANLENVI
Shadow rapporteurCyrus EngererS&DMTENVI
Shadow rapporteurDeirdre CluneEPPIEENVI
Shadow rapporteurIdoia Villanueva RuizThe LeftESENVI
5 documents

Documents

Newest first. Each opens at its source.

1 consultation

Consultations on it

The Commission's Have Your Say consultations linked to this file. Each title opens on the Commission's portal.

ConsultationFeedback deadlineFeedback received
16 Mar 20221

Summary

Generated

This regulation temporarily exempts clinical trial sponsors from specific EU labelling and packaging requirements for investigational medicinal products supplied from the UK to Northern Ireland, and to Cyprus, Ireland, and Malta. It primarily affects pharmaceutical companies and research organizations conducting multinational trials to prevent supply disruptions.

What the workspace adds on this file

Everything above is the public record. Subscribers see this page with their own layer on top.

Why it matters to you

What this file means for your organization, assessed against your own priorities.

What moved

When this file moves, it reaches your own briefing, with a link to its source.

Your contacts on it

Your team's contacts logged against this file: who you met, what was said and the next step.

A first draft

A statement, a member update or a meeting brief on this file, in your organization's voice, with its sources.

Sources: EP Legislative Observatory · EUR-Lex. Record as of 14 Sept 2026. Something wrong on this page? Report an error.

Request access

See this file with your own layer on top: why it matters to you, your contacts on it and a first draft. We’ll schedule a 20-minute walkthrough.

EU-hosted · GDPR-compliant · Trust Center →

By submitting, you agree to our privacy policy.